Employees Retirement System of Texas Makes New $1.65 Million Investment in Genmab A/S (NASDAQ:GMAB)

Employees Retirement System of Texas acquired a new position in shares of Genmab A/S (NASDAQ:GMAB - Free Report) during the 4th quarter, according to its most recent 13F filing with the SEC. The firm acquired 78,950 shares of the company's stock, valued at approximately $1,648,000.

Several other institutional investors and hedge funds have also recently made changes to their positions in the company. Raymond James Financial Inc. acquired a new stake in Genmab A/S in the fourth quarter valued at approximately $2,463,000. AIMZ Investment Advisors LLC purchased a new position in shares of Genmab A/S during the 4th quarter valued at approximately $3,525,000. Mirae Asset Global Investments Co. Ltd. increased its holdings in Genmab A/S by 229.9% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 49,727 shares of the company's stock valued at $1,033,000 after buying an additional 34,652 shares in the last quarter. Blue Trust Inc. increased its position in shares of Genmab A/S by 33.4% in the fourth quarter. Blue Trust Inc. now owns 5,757 shares of the company's stock valued at $120,000 after buying an additional 1,442 shares in the last quarter. Finally, Sei Investments Co. increased its holdings in Genmab A/S by 55.2% in the 4th quarter. Sei Investments Co. now owns 57,702 shares of the company's stock worth $1,205,000 after acquiring an additional 20,525 shares in the last quarter. 7.07% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

GMAB has been the topic of several research reports. William Blair raised shares of Genmab A/S from a "market perform" rating to an "outperform" rating in a research note on Tuesday, March 11th. Leerink Partnrs raised shares of Genmab A/S from a "hold" rating to a "strong-buy" rating in a research note on Thursday, February 13th. BNP Paribas upgraded Genmab A/S from a "strong sell" rating to a "hold" rating in a report on Tuesday, February 11th. HC Wainwright reiterated a "buy" rating and issued a $37.00 price objective (down from $50.00) on shares of Genmab A/S in a research note on Wednesday, April 9th. Finally, Truist Financial reduced their price objective on shares of Genmab A/S from $50.00 to $45.00 and set a "buy" rating on the stock in a report on Tuesday, March 11th. One analyst has rated the stock with a sell rating, three have given a hold rating, eight have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $39.17.

Genmab A/S Stock Performance

Shares of NASDAQ:GMAB traded down $0.39 during trading on Friday, reaching $20.93. 823,934 shares of the stock were exchanged, compared to its average volume of 1,139,590. The firm has a market cap of $13.42 billion, a price-to-earnings ratio of 12.03, a price-to-earnings-growth ratio of 2.65 and a beta of 1.04. The firm's 50-day moving average price is $19.91 and its 200 day moving average price is $20.64. Genmab A/S has a 12-month low of $17.24 and a 12-month high of $28.96.

Genmab A/S (NASDAQ:GMAB - Get Free Report) last issued its quarterly earnings data on Thursday, May 8th. The company reported $0.31 earnings per share for the quarter, beating analysts' consensus estimates of $0.23 by $0.08. The firm had revenue of $715.00 million during the quarter, compared to analyst estimates of $5.17 billion. Genmab A/S had a return on equity of 16.78% and a net margin of 36.30%. As a group, equities research analysts forecast that Genmab A/S will post 1.45 EPS for the current year.

Genmab A/S Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.